RE:RE:RE:Fighting the IBB TrendTime for a reminder that CXR is less dependant (40%) than VRX (100%) on the US market and that less than 10% exposure to Medicare, the highest risk US HC component. CXR has not been implicated on price gouging and in fact presented the competitive pricing in their corporate presentation. I agree, however, that market sentiment is not that discriminate.
select1011 wrote: This is shaping up to be a broad based sell-off day with large volume. The dip in biotech at noon followed the release of documents from Congress citing drug price hikes by at least Turing and VRX. Hearings start Thursday. As the rhetoric and process unfolds - it will weigh on sentiment. A few tough weeks ahead for sure. A good time to look away. GLTA